Compare VLRS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | VOR |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Mexico | United States |
| Employees | 6901 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.2M | 849.5M |
| IPO Year | N/A | 2021 |
| Metric | VLRS | VOR |
|---|---|---|
| Price | $6.96 | $18.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.41 | ★ $45.44 |
| AVG Volume (30 Days) | 870.8K | ★ 909.9K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.69 | N/A |
| Revenue Next Year | $12.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.49 | $0.13 |
| 52 Week High | $10.80 | $49.95 |
| Indicator | VLRS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 67.93 |
| Support Level | $6.39 | $11.38 |
| Resistance Level | $7.00 | $18.60 |
| Average True Range (ATR) | 0.28 | 1.42 |
| MACD | 0.08 | 0.55 |
| Stochastic Oscillator | 17.24 | 79.37 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.